These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Average annual cost of Parkinson's disease in São Paulo, Brazil, with a focus on disease-related motor symptoms. Bovolenta TM; de Azevedo Silva SMC; Saba RA; Borges V; Ferraz HB; Felicio AC Clin Interv Aging; 2017; 12():2095-2108. PubMed ID: 29276379 [TBL] [Abstract][Full Text] [Related]
23. The cost-of-illness and burden-of-disease of treatment-resistant depression in Austria. Walter E; Traunfellner M; Gleitsmann M; Zalesak M; Helmenstein C J Med Econ; 2023; 26(1):1432-1444. PubMed ID: 37768864 [TBL] [Abstract][Full Text] [Related]
24. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease]. Cubo E; Martínez Martin P; González M; Frades B; Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550 [TBL] [Abstract][Full Text] [Related]
25. Economic burden of multimorbidity among older adults: impact on healthcare and societal costs. Picco L; Achilla E; Abdin E; Chong SA; Vaingankar JA; McCrone P; Chua HC; Heng D; Magadi H; Ng LL; Prince M; Subramaniam M BMC Health Serv Res; 2016 May; 16():173. PubMed ID: 27160080 [TBL] [Abstract][Full Text] [Related]
26. The economic burden of depression in Switzerland. Tomonaga Y; Haettenschwiler J; Hatzinger M; Holsboer-Trachsler E; Rufer M; Hepp U; Szucs TD Pharmacoeconomics; 2013 Mar; 31(3):237-50. PubMed ID: 23417609 [TBL] [Abstract][Full Text] [Related]
27. Cost of disorders of the brain in Spain. Parés-Badell O; Barbaglia G; Jerinic P; Gustavsson A; Salvador-Carulla L; Alonso J PLoS One; 2014; 9(8):e105471. PubMed ID: 25133395 [TBL] [Abstract][Full Text] [Related]
28. Economic burden of late presentation in HIV disease in Austria: a comparison of the initial costs imposed by advanced HIV disease vs. non-late presentation. Grabmeier-Pfistershammer K; Rieger A; Schröck T; Schlag M Wien Klin Wochenschr; 2013 Jul; 125(13-14):402-7. PubMed ID: 23807043 [TBL] [Abstract][Full Text] [Related]
29. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia. Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991 [TBL] [Abstract][Full Text] [Related]
30. [Direct costs for Parkinson's treatment in private neurology practices in Berlin]. Ehret R; Balzer-Geldsetzer M; Reese JP; Dodel I; Becker E; Christopher A; Friedrich H; Kraemer S; Lüer W; Müngersdorf M; Puzich R; Rohr A; Schultes-Platzek I; Siefjediers V; Tiel-Wilck K; Oertel WH; Dodel R Nervenarzt; 2009 Apr; 80(4):452-8. PubMed ID: 19252890 [TBL] [Abstract][Full Text] [Related]
31. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Dodel RC; Höffken H; Möller JC; Bornschein B; Klockgether T; Behr T; Oertel WH; Siebert U Mov Disord; 2003 Oct; 18 Suppl 7():S52-62. PubMed ID: 14531047 [TBL] [Abstract][Full Text] [Related]
32. Low-, moderate-, and high-risk obesity in association with cost drivers, costs over the lifecycle, and life expectancy. Reitzinger S; Czypionka T BMC Public Health; 2024 Jul; 24(1):2069. PubMed ID: 39085809 [TBL] [Abstract][Full Text] [Related]
33. Economic burden of Parkinson's disease in Singapore. Zhao YJ; Tan LC; Li SC; Au WL; Seah SH; Lau PN; Luo N; Wee HL Eur J Neurol; 2011 Mar; 18(3):519-26. PubMed ID: 20840378 [TBL] [Abstract][Full Text] [Related]
34. [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs]. Dodel RC; Singer M; Köhne-Volland R; Selzer R; Scholz W; Rathay B; Oertel WH Nervenarzt; 1997 Dec; 68(12):978-84. PubMed ID: 9465341 [TBL] [Abstract][Full Text] [Related]
35. The economic burden of pediatric growth hormone deficiency in Italy: a cost of illness study. Cappa M; Pozzobon G; Orso M; Maghnie M; Patti G; Spandonaro F; Granato S; Novelli G; La Torre D; Salerno M; Polistena B J Endocrinol Invest; 2024 Jul; 47(7):1743-1750. PubMed ID: 38198073 [TBL] [Abstract][Full Text] [Related]
36. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292 [TBL] [Abstract][Full Text] [Related]
38. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study. Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605 [TBL] [Abstract][Full Text] [Related]
39. [Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study]. Marcellusi A; Viti R; Incorvaia C; Mennini FS Recenti Prog Med; 2015 Oct; 106(10):517-27. PubMed ID: 26442978 [TBL] [Abstract][Full Text] [Related]
40. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis]. Wolfenstetter SB Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]